Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 18, 2019updated 23 Dec 2019 8:35am

Novo Nordisk reports positive data for oral semaglutide

Novo Nordisk has reported positive results from the Phase IIIa PIONEER clinical trial programme of oral semaglutide to treat type 2 diabetes patients.

Novo Nordisk has reported positive results from the Phase IIIa PIONEER clinical trial programme of oral semaglutide to treat type 2 diabetes patients.

According to the data from an exploratory analysis of the programme, 3mg, 7mg and 14mg doses of the drug led to glycaemic control in patients across baseline HbA1c levels.

However, the 7mg and 14mg doses showed higher HbA1c reductions compared to Jardiance (empagliflozin), Januvia (sitagliptin), Victoza (liraglutide) or placebo.

Oral semaglutide is an investigational glucagon-like peptide-1 (GLP-1) analogue formulated as a pill for once-daily use.

The oral formulation was assessed in a total of 9,543 type 2 diabetes patients enrolled across ten trials under the PIONEER programme.

In the exploratory analysis, findings from 5,657 patients in the PIONEER 1-5, 7 and 8 trials were grouped by study based on baseline HbA1c.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

PIONEER 1 compared oral semaglutide with diet and exercise, while PIONEER 2 compared the investigational drug with 25mg empagliflozin and PIONEER 4 with 1.8mg liraglutide.

During the PIONEER 3 and 7 studies, oral semaglutide was assessed against 100mg sitagliptin, and PIONEER 8 involved evaluation as an add-on to insulin.

The proportion of patients reaching an HbA1c target of <7% was observed to be higher with 7mg and 14mg oral semaglutide versus all comparators across all HbA1c baseline subgroups.

The safety profile of oral semaglutide across the programme was also found to be consistent with the GLP-1 receptor agonist class and similar to that of subcutaneous semaglutide.

Novo Nordisk executive vice-president and chief science officer Mads Krogsgaard Thomsen said: “This analysis reinforces the findings seen throughout the PIONEER trial programme, demonstrating oral semaglutide’s efficacy in HbA1c reductions compared to commonly used type 2 diabetes treatments.

“If approved, oral semaglutide will become the first and only oral GLP-1 receptor agonist with the potential to help people with uncontrolled type 2 diabetes better manage their condition.”

An injection form of semaglutide is indicated to improve glycaemic control in adults with type 2 diabetes as an adjunct to diet and exercise.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU